Stock listing

Frankfurt:ER4 Emergent BioSolutions Inc. Aktie

German listing (Frankfurt) of Emergent BioSolutions Inc. · home listing NYSE:EBS

Follow Emergent BioSolutions Inc. into a list and get an email when it puts out news.

Share price · FWB:ER4

€4.62 EUR -0.42 (-8.4%)

Close on Nov 20, 2026

Past year -40.4% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
€4.62 – €4.62 EURNov 20, 2026
Market cap
€237.0M EURAt the close on Nov 20, 2026 · price × 51.27M shares outstanding
52-week range
€3.80 – €11.81 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€1,388 EURMedian day 0 shares · 44 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
Emergent BioSolutions Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:EBS · Home$5.05 USD-0.45 (-8.2%)1,389,025$5.08$5.24$4.981$5.50Close on Nov 20, 2026
LSE:0IGA$5.07 USD-0.01 (-0.2%)336$5.14$5.23$4.96$5.081Close on Nov 20, 2026
Frankfurt:ER4€4.622 EUR-0.423 (-8.4%)—€4.622€4.622€4.622€5.045Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:ER4 · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€5.142-0.106-2.0%€5.142€5.142€5.1420
€5.248-0.239-4.4%€5.248€5.248€5.2483,926
€5.487-0.882-13.8%€5.487€5.487€5.4873,926
€6.369+0.347+5.8%€4.897€6.426€4.8960
€6.022-0.304-4.8%€6.022€6.022€6.0220
€6.326+0.048+0.8%€6.326€6.326€6.3262,254
€6.278+0.379+6.4%€6.278€6.278€6.278600
€5.899+0.26+4.6%€5.899€5.899€5.8990
€5.639+0.081+1.5%€5.639€5.639€5.6390
€5.558+0.092+1.7%€5.558€5.558€5.5580
€5.466+0.068+1.3%€5.466€5.466€5.4660
€5.398-0.166-3.0%€5.398€5.398€5.3980
€5.564-0.056-1.0%€5.564€5.564€5.5640
€5.62-0.061-1.1%€5.62€5.62€5.620
€5.681-0.656-10.4%€5.681€5.681€5.6810
€6.337+0.258+4.2%€6.337€6.337€6.3370
€6.079-0.029-0.5%€6.079€6.079€6.0790
€6.108-0.057-0.9%€6.108€6.108€6.1080
€6.165-0.125-2.0%€6.165€6.165€6.1650
€6.29+0.234+3.9%€6.295€6.295€6.206200
€6.056-0.166-2.7%€6.056€6.056€6.0560
€6.222+0.054+0.9%€6.245€6.25€6.142200
€6.168-0.402-6.1%€6.168€6.168€6.1680
€6.57-0.171-2.5%€6.564€6.604€6.525100
€6.741+1.106+19.6%€5.654€6.758€5.654814
€5.635-0.172-3.0%€5.635€5.635€5.6350
€5.807-0.241-4.0%€5.807€5.807€5.8070
€6.048+0.081+1.4%€6.048€6.048€6.0480
€5.967+0.069+1.2%€5.967€5.967€5.9670
€5.898+0.052+0.9%€5.901€5.901€5.879100
€5.846+0.101+1.8%€5.846€5.846€5.8460
€5.745-0.033-0.6%€5.745€5.745€5.7450
€5.778+0.173+3.1%€5.778€5.778€5.7780
€5.605-0.289-4.9%€5.605€5.605€5.6050
€5.894-0.188-3.1%€5.894€5.894€5.8940
€6.082+0.225+3.8%€6.082€6.082€6.0820
€5.857+0.381+7.0%€5.857€5.857€5.8570
€5.476+0.031+0.6%€5.476€5.476€5.4760
€5.445+0.169+3.2%€5.445€5.445€5.4450
€5.276+0.264+5.3%€5.276€5.276€5.2760
€5.012+0.187+3.9%€5.012€5.012€5.0120
€4.825-0.167-3.3%€4.825€4.825€4.8250
€4.992-0.294-5.6%€5.078€5.084€4.958550
€5.286+0.019+0.4%€5.286€5.286€5.2860
€5.267-0.081-1.5%€5.267€5.267€5.2671,000
€5.348-0.153-2.8%€5.348€5.348€5.3480
€5.501+0.195+3.7%€5.501€5.501€5.5010
€5.306+0.12+2.3%€5.306€5.306€5.3060
€5.186+0.013+0.3%€5.186€5.186€5.1860
€5.173+0.146+2.9%€5.088€5.206€5.06380
€5.027-0.07-1.4%€5.027€5.027€5.0270
€5.097+0.346+7.3%€5.097€5.097€5.0970
€4.751+0.324+7.3%€4.751€4.751€4.7510
€4.427+0.098+2.3%€4.427€4.427€4.4270
€4.329+0.207+5.0%€4.329€4.329€4.329300
€4.122-0.03-0.7%€4.122€4.122€4.1220
€4.152+0.211+5.4%€4.152€4.152€4.1520
Ticker
Frankfurt:ER4
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Emergent BioSolutions Inc. news

Emergent BioSolutions Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
36 in the last 12 months · 70 in all · newest Nov 16, 2026 · oldest 2025
Calls
26 calls with a replay · 26 with a transcript · latest Nov 2, 2026
Decks
46 decks · latest Nov 2, 2026

Where Emergent BioSolutions Inc. is listed

ListingExchangeCountryCurrency
NYSE:EBS · Home listingNYSEUnited StatesUSD
gettex:ER4gettexGermanyEUR
Stuttgart:ER4StuttgartGermanyEUR
Tradegate:ER4TradegateGermanyEUR
Lang & Schwarz:A0LC2WLang & SchwarzGermanyEUR
LS Exchange:A0LC2WLS ExchangeGermanyEUR
LSE:0IGALSEUnited KingdomUSD
Frankfurt:ER4 · This pageFrankfurtGermanyEUR
BOATS:EBSBOATSUnited StatesUSD
BX Swiss:ER4BX SwissSwitzerlandCHF
Dusseldorf:ER4DusseldorfGermanyEUR
Munich:ER4MunichGermanyEUR

Valuation

EV/sales 0.9× against a median of 2.2×: 2nd lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$598.2M USD
P/E
Loss
EV/sales
0.9×
EV/EBITDA
Negative EBITDA
Price/book
0.8×
Gross margin
48.4%
Operating margin
−27.7%
Net margin
−40.2%
Debt to equity
1.6×
Beta vs S&P 500
1.17

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Emergent BioSolutions Inc. · NYSE:EBSUS$259.6MUS$598.2Mn/a0.9×n/a0.8×−40.2%1.6×1.17
Deva Holding A.S. · BIST:DEVAUS$276.8MUS$244.9Mn/a0.6×4.4×0.4×−3.9%0.1×n/a
Honz Pharmaceutical Co., Ltd. Class A · SZSE:300086US$276.0MUS$298.2Mn/a5.9×n/a2.2×−62.4%0.2×n/a
Shandong Sito Bio-technology Co., Ltd. Class A · SZSE:300583US$272.2MUS$254.6M62.3×1.5×n/a1.0×2.6%0.1×n/a
Lavipharm SA · ATHEX:LAVIUS$271.0MUS$309.1M41.2×4.5×22.8×4.4×9.6%0.7×n/a
Zhejiang East Asia Pharmaceutical Co., Ltd. Class A · SSE:605177US$264.1MUS$340.3Mn/a2.4×n/a1.1×−21.8%0.5×n/a
Jilin Jian Yisheng Pharmaceutical Co., Ltd. Class A · SZSE:002566US$260.3MUS$189.9M66.4×2.1×n/a0.8×4.4%0.1×n/a
Hua Medicine Ltd. · HKEX:2552US$256.7MUS$148.9M1.6×2.1×n/a1.7×224.4%0.4×n/a
Antibiotice SA · BVB:ATBUS$256.3MUS$267.7M154×2.1×16.9×1.3×1.3%0.1×n/a
Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A · SZSE:300254US$256.0MUS$273.8M76.4×2.3×n/a3.4×2.8%0.5×n/a
Protalix BioTherapeutics, Inc. (de) · AMEX:PLXUS$244.5MUS$205.1M11.9×2.4×7.7×3.0×24.3%0.1×1.05
Median of the othersUS$262.2MUS$261.1M62.3×2.2×12.3×1.5×2.7%0.1×1.05

Forecasts

2 strong buy · 1 sell · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
10.00 USD · Analysts' mean
EPS, year to Dec 2026
0.29 · 2 analysts
Revenue, year to Dec 2026
646.8M · 3 analysts

Team and board

Officers

OfficerRole
Joseph PapaPresident and Chief Executive Officer
Jessica PerlSenior Vice President, General Counsel and Corporate Secretary
Bill HartzelSenior Vice President, Manufacturing and Bioservices
Coleen GlessnerExecutive Vice President Quality and Ethics and Compliance
Michelle PepinSenior Vice President and Chief Human Resources Officer
Paul WilliamsSenior Vice President, Products Business
Richard S. LindahlExecutive Vice President
Stephanie DuatschekExecutive Vice President, Chief Growth Officer

Board

DirectorRole
Zsolt HarsanyiIndependent Director, Chairman of the Board
Don DeGolyerIndependent Director
John D. FowlerIndependent Director
Kathryn C. ZoonIndependent Director
Kay NiedzwieckiDirector
Keith KatkinIndependent Director
Marvin WhiteIndependent Director
Neal FowlerIndependent Director
Ronald B. RichardIndependent Director
Sujata DayalIndependent Director

Events

Calls

CallWhenStatus
Emergent BioSolutions (NYSE:EBS) Q3 2026 Earnings CallMon, Nov 02, 2026 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q2 2026 Earnings CallWed, Aug 05, 2026 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q1 2026 Earnings CallThu, Apr 30, 2026 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q4 2025 Earnings CallThu, Feb 26, 2026 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q3 2025 Earnings CallWed, Oct 29, 2025 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q2 2025 Earnings CallWed, Aug 06, 2025 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q1 2025 Earnings CallWed, May 07, 2025 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q4 2024 Earnings CallTue, Mar 04, 2025 · 4:00 AM ETReplay
Emergent BioSolutions (NYSE:EBS) Q3 2024 Earnings CallWed, Nov 06, 2024 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q2 2024 Earnings CallTue, Aug 06, 2024 · 5:00 PM ETReplay
All 26 calls
CallWhenStatus
Emergent BioSolutions (NYSE:EBS) Q1 2024 Earnings CallWed, May 01, 2024 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q4 2023 Earnings CallWed, Mar 06, 2024 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q3 2023 Earnings CallThu, Nov 02, 2023 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q2 2023 Earnings CallTue, Aug 08, 2023 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q1 2023 Earnings CallTue, May 09, 2023 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q4 2022 Earnings CallMon, Feb 27, 2023 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q3 2022 Earnings CallTue, Nov 08, 2022 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q2 2022 Earnings CallMon, Aug 01, 2022 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q1 2022 Earnings CallThu, Apr 28, 2022 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q4 2021 Earnings CallThu, Feb 24, 2022 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q3 2021 Earnings CallThu, Nov 04, 2021 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q2 2021 Earnings CallThu, Jul 29, 2021 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q1 2021 Earnings CallThu, Apr 29, 2021 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q4 2020 Earnings CallThu, Feb 18, 2021 · 5:00 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q3 2020 Earnings CallThu, Nov 05, 2020 · 10:30 PM ETReplay
Emergent BioSolutions (NYSE:EBS) Q2 2020 Earnings CallThu, Jul 30, 2020 · 12:00 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 2, 2026 · After close−3.0%
Q2 2026Aug 5, 2026 · After close−29.6%
Q1 2026Apr 30, 2026 · After close+2.9%
Q4 2025Feb 26, 2026−26.0%
Q3 2025Oct 29, 2025 · After close+36.6%
Q2 2025Aug 6, 2025 · After close+36.6%
Q1 2025May 7, 2025 · After close+34.2%
Q4 2024Mar 4, 2025 · Before open−6.4%
Q3 2024Nov 6, 2024 · After close+19.6%
Q2 2024Aug 6, 2024 · After close−42.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 1, 2024 · After close+71.0%
Q4 2023Mar 6, 2024 · After close−15.0%
Q3 2023Dec 11, 2023 · Before open−14.9%
Q2 2023Aug 8, 2023 · After close−17.8%
Q1 2023May 9, 2023 · After close+11.4%
Q4 2022Feb 27, 2023 · After close−11.6%
Q3 2022Nov 8, 2022 · After close−34.9%
Q2 2022Aug 1, 2022 · After close−11.6%
Q1 2022Apr 28, 2022 · After close−11.6%
Q4 2021Feb 24, 2022 · After close−6.4%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings35 slidesNov 2, 2026
H.C. Wainwright 28th Annual Global Investment Conference (September 2026)Conference31 slidesSep 14, 2026
Q2 2026 Earnings PresentationEarnings34 slidesAug 5, 2026
Q1 2026 Earnings PresentationEarnings36 slidesApr 30, 2026
Q4 2025 Earnings PresentationEarnings40 slidesFeb 26, 2026
44th Annual J.P. Morgan Healthcare Conference (January 2026)Conference21 slidesJan 14, 2026
Q3 2025 Earnings PresentationEarnings36 slidesOct 29, 2025
Q2 2025 Earnings PresentationEarnings32 slidesAug 6, 2025
Q1 2025 Earnings PresentationEarnings31 slidesMay 7, 2025
Q4 2024 Earnings PresentationEarnings40 slidesMar 4, 2025
All 46 decks
DeckKindSlidesDate
43rd Annual J.P. Morgan Healthcare Conference (January 2025)Conference41 slidesJan 15, 2025
Q3 2024 Earnings PresentationEarnings42 slidesNov 6, 2024
Q2 2024 Earnings PresentationEarnings41 slidesAug 6, 2024
Shareholder Meeting (May 2024)Shareholder meeting8 slidesMay 29, 2024
Q1 2024 Earnings PresentationEarnings32 slidesMay 1, 2024
Q4 2023 Earnings PresentationEarnings31 slidesMar 6, 2024
42nd Annual J.P. Morgan Healthcare Conference 2024Conference28 slidesJan 9, 2024
Q3 2023 Earnings PresentationEarnings23 slidesNov 2, 2023
Q2 2023 Earnings PresentationEarnings28 slidesAug 8, 2023
Shareholder Meeting (May 2023)Shareholder meeting7 slidesMay 31, 2023
Q1 2023 Earnings PresentationEarnings30 slidesMay 9, 2023
Q4 2022 Earnings PresentationEarnings31 slidesFeb 27, 2023
Q3 2022 Earnings PresentationEarnings26 slidesNov 8, 2022
Q2 2022 Earnings PresentationEarnings25 slidesAug 3, 2022
Q2 2022 Earnings PresentationEarnings23 slidesAug 1, 2022
Shareholder Meeting (May 2022)Shareholder meeting8 slidesMay 27, 2022
Q1 2022 Earnings PresentationEarnings22 slidesApr 28, 2022
FY2021 Earnings PresentationEarnings27 slidesFeb 24, 2022
40th Annual J.P. Morgan Healthcare Conference (January 2022)Conference22 slidesJan 10, 2022
Q3 2021 Earnings PresentationEarnings25 slidesNov 4, 2021
Q2 2021 Earnings PresentationEarnings24 slidesJul 29, 2021
Shareholder Meeting (May 2021)Shareholder meeting8 slidesMay 25, 2021
Q1 2021 Earnings PresentationEarnings23 slidesApr 29, 2021
39th Annual J.P. Morgan Healthcare Conference 2021Conference26 slidesJan 11, 2021
Q3 2020 Earnings PresentationEarnings34 slidesNov 5, 2020
Q2 2020 Earnings PresentationEarnings46 slidesJul 30, 2020
Q1 2020 Earnings PresentationEarnings16 slidesApr 30, 2020
38th Annual J.P. Morgan Healthcare Conference (January 2020)Conference30 slidesJan 13, 2020
37th Annual J.P. Morgan Healthcare Conference 2019Conference20 slidesJan 7, 2019
Merger or Acquisition (August 2018)Merger or acquisition23 slidesAug 9, 2018
J.P. Morgan Healthcare Conference 2018Conference17 slidesJan 8, 2018
J.P. Morgan Healthcare Conference 2017Conference18 slidesJan 9, 2017
J.P. Morgan Healthcare Conference 2016Conference25 slidesJan 11, 2016
Merger or Acquisition (August 2015)Merger or acquisition14 slidesAug 6, 2015
Merger or Acquisition (December 2013)Merger or acquisition20 slidesDec 12, 2013
Investor Presentation (August 2010)Investor deck14 slidesAug 19, 2010

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue742.9M1.04B1.05B1.12B1.77B1.58B1.11B782.4M560.9M488.8M
Cost of revenue326.2M681.3M705.4M693.1M748.1M537.0M433.5M322.3M187.7M126.3M
Gross profit416.7M362.3M317.6M383.0M891.3M925.2M672.5M460.1M373.2M362.5M
Research and development53.2M70.7M111.4M188.3M235.2M237.9M226.2M142.8M97.4M106.9M
Selling, general and administrative186.1M308.0M368.4M339.5M348.7M304.1M273.5M202.5M142.9M143.1M
Operating income100.1M-108.7M-726.4M-170.0M341.4M438.5M114.1M89.8M124.3M105.5M
Depreciation and amortization95.8M108.8M125.1M143.3M123.8M50.1M49.5M36.3M32.2M28.0M
EBITDA195.9M100.0K-601.3M-26.7M465.2M488.6M163.6M126.1M156.5M133.5M
Interest expense59.3M71.0M87.9M37.3M34.5M31.3M38.4M9.90M6.60M7.60M
Income before tax82.8M-142.9M-731.2M-219.0M303.2M411.9M77.4M81.5M118.6M99.2M
Income tax30.2M47.7M29.3M-7.40M83.7M106.1M22.9M18.8M36.0M36.7M
Net income52.6M-190.6M-760.5M-211.6M219.5M305.8M54.5M62.7M82.6M51.8M
Earnings per share, basic0.98-3.60-14.85-4.224.105.801.061.251.981.29
Earnings per share, diluted0.93-3.60-14.85-4.224.065.681.041.221.711.13

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents205.4M99.5M111.7M642.6M576.1M621.3M167.8M112.2M178.3M271.5M
Receivables84.2M154.5M191.0M159.2M278.9M230.9M270.7M262.5M143.7M138.5M
Inventory343.4M311.7M328.9M350.7M344.5M307.0M222.5M205.8M142.8M74.0M
Current assets662.5M598.7M679.5M1.21B1.27B1.20B686.2M620.8M485.4M510.2M
Property, plant and equipment205.4M270.6M382.8M817.6M800.1M644.1M542.3M510.2M407.2M376.4M
Goodwill000218.2M224.9M266.7M266.6M259.7M49.1M41.0M
Total assets1.32B1.39B1.82B3.17B2.96B2.88B2.33B2.23B1.07B970.1M
Accounts payable55.6M60.9M112.2M103.5M128.9M136.1M94.8M80.7M41.8M34.6M
Current liabilities132.2M162.4M651.3M1.23B374.0M384.5M216.3M200.4M100.1M105.9M
Long-term debt572.1M663.7M446.5M448.5M809.4M841.0M798.4M784.5M13.5M248.1M
Total debt589.7M700.0M868.4M1.41B849.6M885.5M822.5M808.8M13.6M248.1M
Total liabilities796.0M906.9M1.17B1.78B1.35B1.44B1.24B1.22B157.9M373.9M
Shareholders' equity522.6M482.8M649.3M1.39B1.61B1.45B1.09B1.01B912.3M596.2M
Shares outstanding52.1M54.3M52.2M50.1M51.3M53.1M51.7M51.2M49.4M40.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations170.6M58.7M-206.3M-34.1M320.2M536.9M188.0M41.8M208.1M54.6M
Capital spending-13.8M-22.9M-51.6M-115.8M-224.1M-141.9M-86.9M-72.1M-54.8M-76.2M
Free cash flow156.8M35.8M-257.9M-149.9M96.1M395.0M101.1M-30.3M153.3M-21.6M
Cash from investing69.4M125.2M212.3M-381.3M-224.1M-151.9M-96.9M-897.2M-249.9M-76.2M
Cash from financing-136.6M-190.0M-535.7M481.2M-141.0M69.5M-35.9M788.7M-51.4M-19.8M
Share buybacks-24.9M00-82.1M-106.0M00-100.0K-33.1M0
Change in cash103.5M-6.10M-530.9M66.3M-45.2M453.5M55.6M-66.9M-93.2M-41.3M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 4, 2026Current reportSEC
10-Q · Quarterly reportNov 2, 2026Quarterly reportSEC
8-K · Current reportNov 2, 2026ResultsSEC
8-K · Current reportOct 16, 2026Management or board changeSEC
144 · Notice of proposed saleOct 7, 2026Other filingsSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 14, 2026Current reportSEC
8-K · Current reportSep 1, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
3 · Initial statement of ownershipAug 12, 2026Insider tradeSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 31, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 28, 2026Big-stake noticeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
8-K · Current reportJun 29, 2026Material contractSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
10-Q · Quarterly reportApr 30, 2026Quarterly reportSEC
S-8 · Registration statement for employee plansApr 30, 2026Offer documentSEC
8-K · Current reportApr 30, 2026ResultsSEC
144 · Notice of proposed saleApr 30, 2026Other filingsSEC
8-K · Current reportApr 30, 2026Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialApr 27, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialApr 22, 2026Meeting noticeSEC
8-K · Current reportApr 16, 2026Material contractSEC
DEFA14A · Additional proxy materialApr 16, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialApr 16, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 9, 2026Big-stake noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersMar 20, 2026Annual reportSEC
DEFA14A · Additional proxy materialMar 20, 2026Meeting noticeSEC
DEF 14A · Proxy statementMar 20, 2026Meeting noticeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
8-K · Current reportMar 3, 2026Management or board changeSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
8-K · Current reportJan 14, 2026Current reportSEC
8-K · Current reportJan 12, 2026Current reportSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
8-K · Current reportDec 12, 2025Current reportSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
144 · Notice of proposed saleDec 5, 2025Other filingsSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
8-K · Current reportNov 12, 2025Management or board changeSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
144 · Notice of proposed saleNov 7, 2025Other filingsSEC
10-Q · Quarterly reportOct 29, 2025Quarterly reportSEC
8-K · Current reportOct 29, 2025ResultsSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
144 · Notice of proposed saleOct 7, 2025Other filingsSEC
8-K · Current reportSep 11, 2025Material contractSEC
8-K · Current reportSep 5, 2025Current reportSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 18, 2025Other filingsSEC
144 · Notice of proposed saleAug 15, 2025Other filingsSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
CORRESP · Letter to the SECAug 13, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 13, 2025Other filingsSEC
144 · Notice of proposed saleAug 12, 2025Other filingsSEC
S-3 · Registration statementAug 7, 2025Offer documentSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJul 15, 2025Insider tradeSEC
8-K · Current reportJun 24, 2025Current reportSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
8-K · Current reportMay 23, 2025Current reportSEC
144 · Notice of proposed saleMay 23, 2025Other filingsSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
8-K · Current reportMay 6, 2025Meeting outcomeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipApr 9, 2025Insider tradeSEC
4 · Change in ownershipApr 9, 2025Insider tradeSEC
4/A · Change in ownership, amendedApr 9, 2025Insider tradeSEC
8-K · Current reportMar 31, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveMar 25, 2025Other filingsSEC
424B3 · ProspectusMar 24, 2025Offer documentSEC
8-K · Current reportMar 21, 2025Current reportSEC
DEF 14A · Proxy statementMar 21, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialMar 21, 2025Meeting noticeSEC
ARS · Annual report to shareholdersMar 21, 2025Annual reportSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
144 · Notice of proposed saleMar 12, 2025Other filingsSEC
144 · Notice of proposed saleMar 12, 2025Other filingsSEC
8-K · Current reportMar 10, 2025Current reportSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
POS AM · Amendment to an effective registrationMar 4, 2025Offer documentSEC
POS EXMar 4, 2025Other filingsSEC
424B3 · ProspectusMar 4, 2025Offer documentSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
10-K · Annual reportMar 3, 2025Annual reportSEC
8-K · Current reportMar 3, 2025ResultsSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
8-K · Current reportJan 15, 2025Current reportSEC
8-K · Current reportJan 14, 2025Current reportSEC
8-K · Current reportJan 8, 2025Current reportSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 5, 2024Other filingsSEC
424B3 · ProspectusDec 4, 2024Offer documentSEC
CORRESP · Letter to the SECDec 2, 2024Other filingsSEC
S-1/A · Registration statement, amendedDec 2, 2024Offer documentSEC
3 · Initial statement of ownershipNov 21, 2024Insider tradeSEC
UPLOAD · Letter from the SECNov 18, 2024Other filingsSEC
4 · Change in ownershipNov 14, 2024Insider tradeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 13, 2024Big-stake noticeSEC
144 · Notice of proposed saleNov 12, 2024Other filingsSEC
3 · Initial statement of ownershipNov 12, 2024Insider tradeSEC
S-1 · Registration statementNov 12, 2024Offer documentSEC
144 · Notice of proposed saleNov 12, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
4 · Change in ownershipOct 17, 2024Insider tradeSEC
8-K · Current reportOct 4, 2024Management or board changeSEC
8-K · Current reportOct 2, 2024ResultsSEC
8-K · Current reportSep 17, 2024FinancingSEC
SC 13G/A · Big-stake notice, amendedSep 10, 2024Big-stake noticeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Emergent BioSolutions Inc.’s releases · as of Oct 26, 2026

Common shares
51,415,182
Fully diluted
51,415,182

Fully diluted

LineSharesAs of
Common shares51,415,182Oct 26, 2026

Share count over time

CountShares
Oct 26, 202651,415,182

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
BlackRock5.17M10.1%US$34.1M+453KNov 13, 2026
Vanguard3.74M7.3%US$24.7M+105KNov 16, 2026
American Century3.31M6.4%US$21.9M+542KNov 20, 2026
State Street2.71M5.3%US$17.9M−216KNov 12, 2026
Dimensional2.57M5.0%US$16.9M−510KNov 4, 2026
Lsv Asset Management1.99M3.9%US$13.1M+294KNov 6, 2026
Acadian Asset Management LLC1.93M3.8%US$12.8M+589KNov 9, 2026
Millennium1.88M3.7%US$12.4M+809KNov 16, 2026
Oak Hill Advisors LP1.51M2.9%US$9.99M+401KNov 16, 2026
Geode Capital1.27M2.5%US$8.39M−66,082Nov 6, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Prescott Group Capital Management, L.L.C.1.14M2.2%US$7.55M+371KOct 30, 2026
Schwab1.11M2.2%US$7.33M−89,840Nov 16, 2026
D. E. Shaw & Co., Inc.968K1.9%US$6.39M+68,174Nov 16, 2026
AQR Capital Management LLC918K1.8%US$6.06M−123KNov 16, 2026
Goldman Sachs912K1.8%US$6.02M−124KNov 16, 2026
Prudential Financial Inc873K1.7%US$5.76M+67,329Nov 16, 2026
Trexquant Investment LP825K1.6%US$5.44M+377KNov 16, 2026
Fidelity733K1.4%US$4.84M+518KNov 10, 2026
Renaissance Technologies724K1.4%US$4.78M+40,900Nov 12, 2026
Allianz674K1.3%US$4.45M+130KNov 16, 2026
Northern Trust587K1.1%US$3.87M−34,744Nov 16, 2026
Ancora Advisors LLC578K1.1%US$3.81M−490KNov 16, 2026
Morgan Stanley546K1.1%US$3.6M+75,979Nov 13, 2026
O'Shaughnessy Asset Management, LLC504K0.98%US$2.97M+63,694Nov 12, 2026
Federated Hermes, Inc.471K0.92%US$3.11M−360KNov 12, 2026
Russell Investments Group, Ltd.467K0.91%US$3.08M−392KNov 6, 2026
Panagora Asset Management Inc453K0.88%US$2.99M+123KNov 12, 2026
Bridgeway Capital Management, LLC378K0.74%US$2.49MNewNov 16, 2026
UBS328K0.64%US$2.17M−37,816Nov 16, 2026
Squarepoint Ops LLC317K0.62%US$2.09M+169KNov 9, 2026
Values First Advisors, Inc.296K0.58%US$1.95M−5,390Oct 23, 2026
Truist Financial Corp230K0.45%US$1.52M+186KOct 30, 2026
BNY216K0.42%US$1.43M−3,514Nov 5, 2026
Soviero Asset Management, LP210K0.41%US$1.39M+110KNov 16, 2026
Globeflex Capital L P199K0.39%US$1.31M−42,772Nov 16, 2026
Wellington178K0.35%US$1.18M+26,157Nov 16, 2026
Wolverine Asset Management LLC175K0.34%US$1.15MNo changeNov 2, 2026
Empowered Funds, LLC168K0.33%US$1.11MNewNov 13, 2026
Bank of America163K0.32%US$1.08M+11,072Nov 16, 2026
Susquehanna161K0.31%US$1.07M+68,354Nov 16, 2026
Two Sigma160K0.31%US$1.05M−329KNov 16, 2026
ExodusPoint Capital Management, LP155K0.30%US$1.02M+111KNov 16, 2026
Principal153K0.30%US$1.01MNewNov 2, 2026
Credit Agricole S A146K0.28%US$966KNo changeNov 13, 2026
Invesco129K0.25%US$854K−16,717Nov 12, 2026
Nomura123K0.24%US$810KNo changeNov 16, 2026
Nuveen119K0.23%US$788K+5,117Nov 10, 2026
Schonfeld Strategic Advisors LLC119K0.23%US$788KNewNov 16, 2026
SummerHaven Investment Management, LLC114K0.22%US$750KNewOct 19, 2026
Quantinno Capital Management LP110K0.21%US$728K+65,482Nov 13, 2026

This page holds 50 of 180 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Avantis U.S. Small Cap Value ETF2.27M4.4%US$20.7M+261KMay 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.71M3.3%US$14.3M+133KJun 30, 2026
Vanguard Total Stock Market Index Fund1.55M3.0%US$13M−54,500Jun 30, 2026
iShares Russell 2000 ETF1.38M2.7%US$11.6M+101KJun 30, 2026
Schwab Fundamental U.S. Small Company ETF758K1.5%US$6.91M−235KMay 31, 2026
U.S. Small Cap Value Portfolio706K1.4%US$5.09M+123KJul 31, 2026
Federated Hermes MDT Small Cap Core Fund630K1.2%US$4.55M+314KJul 31, 2026
Vanguard Extended Market Index Fund593K1.2%US$4.97M−530Jun 30, 2026
Fidelity Small Cap Index Fund569K1.1%US$4.11M+53,359Jul 31, 2026
Vanguard Strategic Equity Fund529K1.0%US$4.43M+63,248Jun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
iShares Russell 2000 Value ETF502K0.98%US$4.21M+58,828Jun 30, 2026
U.S. Targeted Value Portfolio443K0.86%US$3.2M+69,416Jul 31, 2026
Dimensional U.S. Targeted Value ETF375K0.73%US$2.71M+2,232Jul 31, 2026
PIMCO RAE US Small Fund351K0.68%US$2.94M+20,314Jun 30, 2026
iShares Biotechnology ETF344K0.67%US$2.88M−32,932Jun 30, 2026
Ancora/Thelen Small-Mid Cap Fund332K0.65%US$2.78M+227KJun 30, 2026
Dimensional US Small Cap Value ETF304K0.59%US$2.2M+20,453Jul 31, 2026
Fidelity Extended Market Index Fund275K0.54%US$2.51M−1,129May 31, 2026
iShares U.S. Small-Cap Equity Factor ETF268K0.52%US$1.93M+171KJul 31, 2026
Vanguard Russell 2000 Index Fund267K0.52%US$2.44M+8,683May 31, 2026
Schwab U.S. Small-Cap ETF248K0.48%US$2.26M−3,924May 31, 2026
U.S. Small Cap Portfolio227K0.44%US$1.64MNo changeJul 31, 2026
Fidelity Enhanced Small Cap Core ETF188K0.37%US$1.58M+68,182Jun 30, 2026
iShares Micro-Cap ETF175K0.34%US$1.47M+43,786Jun 30, 2026
U.S. Micro Cap Portfolio172K0.34%US$1.24M+3,141Jul 31, 2026
Dimensional U.S. Small Cap ETF170K0.33%US$1.23MNo changeJul 31, 2026
Vanguard Health Care Index Fund158K0.31%US$1.44M−1,333May 31, 2026
LSV Small Cap Value Fund157K0.31%US$1.14MNewJul 31, 2026
Small Cap Value Fund146K0.28%US$1.22MNo changeJun 30, 2026
Schwab Fundamental U.S. Small Company Index Fund143K0.28%US$1.03M−58,696Jul 31, 2026
PGIM Quant Solutions Small-Cap Value Fund141K0.27%US$1.02M+34,700Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF141K0.27%US$1.02MNo changeJul 31, 2026
Avantis U.S. Small Cap Value Fund134K0.26%US$1.22MNo changeMay 31, 2026
Schwab Small-Cap Index Fund127K0.25%US$917K+11,411Jul 31, 2026
Optimum Small-Mid Cap Value Fund123K0.24%US$1.03MNewJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF119K0.23%US$857K−30,268Jul 31, 2026
Mercer US Small/Mid Cap Equity Fund115K0.22%US$966KNewJun 30, 2026
State Street Institutional Small-Cap Equity Fund112K0.22%US$938K−2,890Jun 30, 2026
Schwab Small-Cap Equity Fund99,8200.19%US$721K+44,083Jul 31, 2026
Master Small Cap Index Series99,3520.19%US$833K+13,897Jun 30, 2026
Avantis U.S. Small Cap Equity ETF98,8040.19%US$901K−19,699May 31, 2026
Vanguard U.S. Momentum Factor ETF98,0570.19%US$894K+18,980May 31, 2026
Fidelity Total Market Index Fund97,5450.19%US$890KNo changeMay 31, 2026
AST PGIM Aggressive Multi-Asset Portfolio88,8000.17%US$744K+27,000Jun 30, 2026
Fullerthaler Behavioral Micro-Cap Equity Fund82,1550.16%US$688K+500Jun 30, 2026
Fidelity Series Total Market Index Fund80,0430.16%US$730K+3,531May 31, 2026
WisdomTree U.S. SmallCap Fund76,6760.15%US$643K−1,802Jun 30, 2026
American Beacon Small Cap Value Fund74,1570.14%US$535K−4,293Jul 31, 2026
Fidelity Small Cap Value Index Fund72,6410.14%US$609K+8,116Jun 30, 2026
Nuveen Small Cap Blend Index Fund69,6960.14%US$503K+8,287Jul 31, 2026

This page holds 50 of 196 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
DeGolyer Donald W
Director
Sale17,800USD 7.09US$126KOct 7, 2026
Williams Paul Anthony
Officer: SVP, Products Business
Sale3,000USD 6.53US$19,590Oct 1, 2026
Williams Paul Anthony
Officer: SVP, Products Business
Sale3,000USD 8.40US$25,200Jul 1, 2026
Dayal Sujata Tyagi
Director
Sale12,781USD 8.36US$107KMay 1, 2026
Dayal Sujata Tyagi
Director
Sale980USD 8.94US$8,761May 1, 2026
DeGolyer Donald W
Director
Sale14,527USD 8.36US$121KMay 1, 2026
DeGolyer Donald W
Director
Sale954USD 8.96US$8,548May 1, 2026
Zoon Kathryn C
Director
Sale16,145USD 8.36US$135KMay 1, 2026
Zoon Kathryn C
Director
Sale1,057USD 8.97US$9,481May 1, 2026
Katkin Keith
Director
Sale15,481USD 8.28US$128KApr 30, 2026
All 11 trades
InsiderTradeSharesPriceValueDate
Williams Paul Anthony
Officer: SVP, Products Business
Sale4,000USD 8.44US$33,760Apr 1, 2026

Big stakes

HolderStakeSharesDate
BlackRock, Inc.9.00%4.65MJun 30, 2026
Oak Hill Advisors LP7.50%4.01MSep 30, 2026
American Century Investment Management, Inc.6.50%3.31MSep 30, 2026
Dimensional Fund Advisors LP5.30%2.76MMar 31, 2026
State Street Corp5.10%2.7MDec 31, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Karen Smith
Other companies: Context Therapeutics Inc. (Independent Director · Since at least Sep 4, 2024); Skye Bioscience, Inc. (Director · Since at least Jul 2, 2024); Sangamo Therapeutics, Inc. (Director · Since at least Jun 26, 2018); Aurinia Pharmaceuticals Inc (Director · Aug 18, 2023 – Nov 21, 2024 · Past); Quince Therapeutics, Inc. (Chief Medical Officer · May 19, 2022 – Feb 1, 2023 · Past); Tourmaline Bio Inc. (Director · May 16, 2022 – Jun 13, 2023 · Past); Antares Pharma Inc (Director · Mar 1, 2019 – May 24, 2022 · Past); Acceleron Pharma Inc (Director · Nov 15, 2017 – Nov 19, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Jul 15, 2017 – Feb 13, 2018 · Past); Jazz Pharmaceuticals plc (EVP, R&D and CMO · Apr 13, 2015 – Mar 5, 2018 · Past)
EVP, Chief Medical Officer · May 21, 2020 – May 7, 2021 · Past
Louis W Sullivan
Other companies: United Therapeutics Corporation (Director · Since at least Jun 26, 2006); ANI Pharmaceuticals, Inc. (Director · Mar 16, 2006 – Mar 30, 2012 · Past); Henry Schein, Inc. (Director · Mar 2, 2006 – Mar 31, 2016 · Past); Inhibitex Inc (Director · Feb 1, 2006 – Feb 1, 2007 · Past); 3M Company (Director · Dec 31, 2005 – May 9, 2006 · Past); The Cigna Group (Director · Dec 31, 2005 – Jun 1, 2006 · Past); Bristol-Myers Squibb Company (Director · Dec 30, 2005 – Mar 31, 2006 · Past)
Director · Nov 14, 2006 – Apr 30, 2025 · Past
Joseph Papa
Other companies: Milestone Pharmaceuticals Inc. (Independent Non-Executive Director · Since at least Sep 3, 2024); Candel Therapeutics, Inc. (Chairman · Since at least Aug 8, 2022); Bausch + Lomb Corporation (See Remarks, Director · May 5, 2022 – May 5, 2022 · Past); Prometheus Biosciences Inc (Director · Mar 11, 2021 – Jun 16, 2023 · Past); Bausch Health Companies Inc. (Director · May 2, 2016 – May 10, 2022 · Past); Perrigo Company plc (Director · Oct 9, 2006 – Feb 26, 2016 · Past)
President and Chief Executive Officer · Since at least Feb 21, 2024
Keith A. Katkin
Other companies: Eledon Pharmaceuticals, Inc. (Chairman of the Board of Directors · Since at least May 10, 2017); Syndax Pharmaceuticals, Inc. (Director · Since at least Mar 29, 2017); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Sep 26, 2018 – Feb 19, 2020 · Past); Rigel Pharmaceuticals, Inc. (Director · Jun 29, 2015 – May 19, 2021 · Past); Carbylan Therapeutics Inc (Director · Apr 8, 2015 – Aug 3, 2015 · Past); Avanir Pharmaceuticals Inc (President and CEO, Director · May 15, 2013 – Dec 15, 2014 · Past)
Independent Director · Since at least Apr 1, 2022
Barry Labinger
Other companies: Checkmate Pharmaceuticals Inc (President and CEO, Director · Aug 6, 2020 – Aug 4, 2021 · Past); Anadys Pharmaceuticals Inc (Director · Mar 11, 2011 – May 27, 2011 · Past); Human Genome Sciences Inc (Exec VP & CCO · Mar 14, 2006 – Jul 30, 2012 · Past)
EVP, Biosciences Div. · Aug 12, 2013 – Nov 13, 2015 · Past
Marvin L. White
Other companies: Aptevo Therapeutics Inc. (Executive Chair · Since at least Jul 29, 2016); CoLucid Pharmaceuticals Inc (Director · Jul 9, 2015 – Mar 1, 2017 · Past); Washington Prime Group Inc (Director · May 8, 2014 – Aug 4, 2014 · Past)
Independent Director · Since at least Jun 1, 2010
Neal Fowler
Other companies: Liquidia Corporation (Chief Executive Officer, Director · Nov 19, 2020 – Nov 19, 2020 · Past); Aralez Pharmaceuticals Inc (Director · Feb 5, 2016 – May 11, 2017 · Past); POZEN Inc (Director · Jun 10, 2010 – Jul 28, 2015 · Past)
Independent Director · Since at least Oct 1, 2023
Richard S. Lindahl
Other companies: Compass Therapeutics, Inc. (Executive Vice President, Chief Financial Officer and Treasurer, Emergent BioSolutions · Since at least Apr 21, 2023); The Corporate Executive Board Company (Chief Financial Officer · Mar 27, 2013 – Apr 27, 2015 · Past); SPRINT Corp (Treasurer · Feb 7, 2006 – Aug 4, 2008 · Past)
Executive Vice President · Since at least Mar 26, 2018
Atul Saran
Other companies: MacroGenics, Inc. (SVP & General Counsel · Jun 5, 2014 – Apr 28, 2017 · Past); Xencor, Inc. (Director · Dec 2, 2013 – Dec 6, 2013 · Past)
EVP, Chief Strat & Dev Officer · Jul 20, 2017 – Feb 28, 2023 · Past
Daniel J. Abdun-Nabi
Other companies: Aptevo Therapeutics Inc. (President · Since at least Aug 1, 2016); Regenxbio Inc. (Director · Aug 5, 2016 – Jun 4, 2021 · Past)
CEO, Director · Nov 14, 2006 – Mar 4, 2019 · Past
All 40 people
PersonSeat
Fuad El-Hibri
Other companies: Aptevo Therapeutics Inc. (Director · Aug 1, 2016 – Dec 3, 2021 · Past)
Director · Nov 14, 2006 – Dec 3, 2021 · Past
George A Joulwan
Other companies: General Dynamics Corporation (Director · Jan 3, 2006 – Mar 12, 2012 · Past)
Director · Jul 17, 2013 – May 26, 2022 · Past
Jennifer Fox
Other companies: Myriad Genetics, Inc. (Chief Legal Officer · Since at least Sep 3, 2024)
EVP, Ext Aff, GC, Corp Sec · Mar 1, 2022 – Jul 11, 2024 · Past
John D Fowler Jr
Other companies: Beverly Enterprises Inc (Director · Mar 14, 2006 – Mar 14, 2006 · Past)
Director · Since at least Mar 1, 2026
John E. Niederhuber
Other companies: Aptevo Therapeutics Inc. (Lead Independent Director · Since at least Aug 1, 2016)
Director · Aug 23, 2010 – May 18, 2016 · Past
Robert Kramer
Other companies: Aptevo Therapeutics Inc. (President, Director · Jul 15, 2016 – Jul 15, 2016 · Past)
President and CEO, Director · May 31, 2013 – Jun 9, 2023 · Past
Zsolt Harsanyi
Other companies: Aptevo Therapeutics Inc. (Director · Since at least Jul 15, 2016)
Independent Director, Chairman of the Board · Since at least Nov 14, 2006
Adam HaveyEVP, Business Operations · Mar 1, 2011 – Jun 9, 2023 · Past
Bill HartzelSenior Vice President, Manufacturing and Bioservices · Since at least Aug 8, 2023
Coleen GlessnerExecutive Vice President Quality and Ethics and Compliance · Since at least Mar 14, 2022
Don DeGolyerDirector · Since at least Oct 1, 2023
Edward ArcuriCOO · Nov 14, 2006 – May 8, 2007 · Past
H Haywood Miller IIIInterim CEO · Jun 24, 2023 – Jun 24, 2023 · Past
Jerome M HauerDirector · Nov 14, 2006 – May 25, 2023 · Past
Jessica PerlSenior Vice President, General Counsel and Corporate Secretary · Since at least Oct 29, 2024
John D. FowlerIndependent Director · Since at least Mar 3, 2026
Katherine StreiEVP, Chief HR Officer · Feb 27, 2018 – Feb 28, 2023 · Past
Kathryn C. ZoonIndependent Director · Since at least Nov 8, 2016
Kay NiedzwieckiDirector · Since at least Nov 4, 2026
Mauro GibelliniSVP, Corporate Dev. · Apr 1, 2007 – Jun 4, 2007 · Past
Michelle PepinSenior Vice President and Chief Human Resources Officer · Since at least Nov 5, 2026
Paul WilliamsSenior Vice President, Products Business · Since at least Jan 9, 2023
Ronald B. RichardIndependent Director · Since at least Oct 17, 2008
Sean KirkEVP, Manufacturing & Tech Ops · Feb 25, 2020 – Mar 31, 2021 · Past
Simon C LowrySVP, R&D, CMO · Since at least Nov 18, 2024
Stephanie DuatschekExecutive Vice President, Chief Growth Officer · Since at least Aug 5, 2026
Steven ChatfieldEVP, BioSciences · Nov 14, 2006 – Mar 14, 2013 · Past
Sue BaileyDirector · Jun 14, 2007 – Mar 4, 2021 · Past
Sujata DayalIndependent Director · Since at least Jul 15, 2022
Thomas ZinkSVP & CMO · Nov 14, 2006 – May 17, 2007 · Past

Open People

Log in to ask 6ix AI your own questions about Emergent BioSolutions Inc.